What do systematic reviews say?

Summary of findings table ‐ Continuation vs reduction of polypharmacy

The review found no eligible studies for this question.

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Continuation vs reduction of polypharmacy

It is very uncertain whether summary of findings table ‐ Continuation changes service use – readmission to hospital – total compared with reduction of polypharmacy (very low certainty).

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 0.75 [0.25, 2.24]
  1 study · 127 participants
  Very low

Summary of findings table ‐ Continuation vs reduction of polypharmacy

It is very uncertain whether summary of findings table ‐ Continuation changes adverse effects – leaving the study early due to adverse effects –… compared with reduction of polypharmacy (very low certainty).

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 4.37 [0.77, 24.88]
  3 studies · 176 participants
  Very low

Summary of findings table ‐ Continuation vs reduction of polypharmacy

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 12 participants
  Very low

Summary of findings table ‐ Continuation vs reduction of polypharmacy

The review found no eligible studies for this question.

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Continuation vs reduction of polypharmacy

Summary of findings table ‐ Continuation may leads to lower leaving the study early due to any reason – overall acceptability… compared with reduction of polypharmacy (low certainty).

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 0.44 [0.29, 0.68]
  5 studies · 319 participants
  Low

Summary of findings table ‐ Continuation vs reduction of polypharmacy

It is very uncertain whether summary of findings table ‐ Continuation changes adverse effects: ≥ 1 adverse effect – total compared with reduction of polypharmacy (very low certainty).

• Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  RR 5 [0.28, 88.53]
  1 study · 14 participants
  Very low